The drug, Cobenfy, developed by U.S. pharma giant Bristol Myers Squibb, works differently from existing treatments, targeting the so-called cholinergic receptors, not the dopamine receptors The drug, Cobenfy, developed by U.S. pharma giant Bristol Myers Squibb, works differently from existing treatments, targeting the so-called cholinergic receptors, not the dopamine receptors Health Health News, Wellbeing Tips, Diseases, Treatment and Nutrition | The Hindu
New drug for schizophrenia has experts excited
